Skip to content
Master Your Money — Master Your Financial Future — Master Your Money — Mastering Markets

Four young Germans rank among the globe's wealthiest individuals, yet their identities remain largely undisclosed to the public.

Young Germans, all under the age of 30, have found their way onto the Forbes billionaires list, yet many remain relatively unknown.

,   and  Administrator
1 min read
Four young Germans have amassed billionaire status, largely remaining obscure on the global stage.
Four young Germans have amassed billionaire status, largely remaining obscure on the global stage.

Four young Germans rank among the globe's wealthiest individuals, yet their identities remain largely undisclosed to the public.

The von Baumbach siblings, Johannes, Franz, Katharina, and Maximilian, are among the wealthiest families in Europe, each holding a fortune of approximately $5.8 billion (€5 billion) according to Forbes. Despite their substantial wealth management, they remain out of the public spotlight, unlike tech giants like Mark Zuckerberg or Elon Musk.

The siblings' wealth management is primarily derived from their inheritance of Boehringer Ingelheim, a global pharmaceutical company founded in 1885 by Albert Boehringer. Boehringer Ingelheim is known for its wide range of medications, including blood thinners, medications for lung diseases, and Type 2 diabetes.

In 2024, Boehringer Ingelheim generated a turnover of around €26.8 billion, with over 54,000 employees at locations such as Dortmund, Vienna, and Shanghai. The company is Germany's largest private pharmaceutical company and a significant player in the global pharmaceutical industry.

The von Baumbach siblings consistently appear on the Forbes list of the wealthiest people in the world, ranking at number 650. Public photos of the siblings are rare, and their parents' identities are not specified in the provided search results.

The siblings, who are in their twenties, were born into wealth management. Johannes is 20, Franz is 24, Katharina is 25, and Maximilian is 27. Despite their young age, they have managed to maintain their privacy, choosing to stay out of the limelight.

Boehringer Ingelheim is a successful and influential pharmaceutical company with a global presence. Its medications for Type 2 diabetes have made a significant impact on the lives of many, contributing to the wealth management of the von Baumbach siblings. The siblings' story serves as a reminder of the power of inheritance and the potential for success in the pharmaceutical industry.

Read also:

Related

Latest